Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ganciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.95 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.95 |
| ▸ | VCP | P55072 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.95 |
| ▸ | PNP | P00491 | 7/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | EDNRA | P25101 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL25915 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481482 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2433042 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10901311 | 0.98 | BLM (0.95) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL3033 | 0.98 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2160505 | 0.98 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11093368 | 0.96 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481442 | 0.96 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL1242615 | 0.96 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10899902 | 0.96 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380831-A | Ganciclovir sodium monohydrate and preparation method thereof | 安徽普利药业有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-1940353-B1 | PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC KERATITIS | BERLIN CHEMIE AG (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20080249061-A1 | film-forming agent selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylate (PA); prevent brivudine photodegradation allowing at the same time excellent tolerability and long-lasting local delivery of the drug | BERLIN-CHEMIE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| CN-101272765-A | Photostable pharmaceutical composition comprising brivudine for the treatment of herpetic keratitis | BERLIN CHEMIE AG (DE) | 2008-09-24 | — | — | CN | disclosed |
| EP-1940353-A2 | PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC KERATITIS | BERLIN-CHEMIE AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007039201-A2 | PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC KERATITIS | BERLIN-CHEMIE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| CN-1125823-C | Ganciclovir sodium hydrate and its preparing process and application | LIU WANZHONG (CN) | 2003-10-29 | — | — | CN | disclosed |
| CN-1383827-A | Prepn of antiviral N-9 substituted guanine medicine powder for injection | LIU WANZHONG (CN) | 2002-12-11 | — | — | CN | disclosed |
| CN-1342651-A | Ganciclovir sodium hydrate and its preparing process and application | LIU WANZHONG (CN) | 2002-04-03 | — | — | CN | disclosed |